PharmaVOICE - 
March 2008
Purchase Issue

In Every Issue
Last Word
Alan C. Moses, M.D., is VP, Chief Medical Officer Worldwide, [...]
By
Talent Pool
Pharma POOL Wendy KOUBA Wyeth Names Communications VP Wyeth, Madison, [...]
By
On the Calendar
March 1718 3rd Imaging in Preclinical &Clinical Drug Development San [...]
By
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES Edge Dynamics [...]
By
What’s New
WHAT’S NEW NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES HealthEd Group [...]
By
PharmaTrax
Best practices in planning and targeting and conducting office calls, [...]
By
For Art’s Sake
There have been more than a few occasions when I [...]
By
PharmaOutlet
Research collaborations can be a very useful adjunct to a [...]
By

Dr. Stewart Lyman

UpFront
DETAILING DUDS Rep Access Continues to Fall Based on a [...]
By
Letter from the Editor
It may not be Jules Verne’s rendition of “Around the [...]
By

Taren Grom, Editor

On The Cover

Global Opportunities
According to Ernst & Young, the sheer volume and growing economic muscle of consumers in emerging markets provide powerful investment incentives for multinational companies (MNCs). In particular, current and projected growth rates for pharmaceutical markets in the BRIC countries and Mexico exceed those in the more mature markets in the United States, Europe, and Japan. [...]
By

Robin Robinson

Features

The Fourth Tier: Tighter Control of Specialty Drugs
Managed MARKETS Managed care organizations are tackling the rising costs and expanding use of specialty products. Specialty drugs, injectable biologics, and other highercost drugs that require close supervision and monitoring are the fastest growing segment of the overall pharmaceutical space. The average annual increase in drug cost expenditures reported in 2007 was 6.9%,accord ing to [...]
By

Denise Myshko

A Strategy for Pharma Diversification
In response to myriad challenges and with the hope of renewing double digit growth, the question becomes whether pharmaceutical firms should hold on to a pure pharmaceutical business model or embrace a more aggressive diversification strategy, says Roger Fournier, a senior executive working at a global pharmaceutical company. Some companies are reducing the breadth of [...]
By
Ted Schroeder — A Thoughtful Note
BY KIM RIBBINK A THOUGHTFUL ote considered approach to leadership has helped Ted Schroeder guide his team through ups and downs and set Cadence Pharmaceuticals on a defined path, one in which a vibrant culture and strong core values are the keys to its longterm success. N A A Photography by nathanpetty.com PV0308 LAYOUT 2/14/08 [...]
By

Kim Ribbink

A Woman’s Heart
Women are six times more likely to die from heart attacks than breast cancer. Car diovascular diseases (CVD), particularly coronary heart disease (CHD) and stroke, remain the leading causes of death of women in America and most developed coun tries, with almost 39% of all female deaths in the United States occurring from CVD. Yet [...]
By

Cynthia Borda

Climbing the Corporate Lattice
BY KIM RIBBINK executive search firm. “People need to be more prepared to work in a number of different companies or settings, including not just pharma but also specialty pharma and startup biotech.” This means there is tremendous movement in the industry, which presents challenges for companies hiring individuals as well as for employees developing [...]
By

Kim Ribbink

User Fees: Devising a Shift in Policy
BY DENISE MYSHKO New laws and regulations aimed at improving reviews of medical devices have been put in place. In September 2007, President George W. Bush signed a broadranging bill that expands the regulatory authority of the Food and Drug Administration. Combined with the legislation were sever al bills that had been pending for some [...]
By

Denise Myshko

Strengthening the Clinical Recruitment Chain
W finding the right population within the right time frame means doing your homework, looking at feasibility data, modeling time frames, metrics, and budget parameters.” Negative press is another uncontrollable factor that can slow patient enrollment, par ticularly if a drug is pulled from the market because of an adverse event and the clinical study [...]
By

Robin Robinson

FEEDBACK